Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting

Xenetic Biosciences, Inc., a company focused on immune-oncology technologies, recently presented positive preclinical data at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. Dr. Reid Bissonnette, the Executive Consultant for Translational Research and Development at Xenetic, participated in a Virtual Investor segment titled "What This Means," where he discussed key insights from a poster presentation. The study highlighted the benefits of DNase I intervention in enhancing CAR-T cell therapy for solid tumors through targeting neutrophil extracellular traps in metastatic melanoma.

The company emphasizes the potential of its DNase technology to improve outcomes in difficult-to-treat cancers, aiming to move its systemic DNase program into clinical settings. Focus areas include pancreatic carcinoma and other advanced solid tumors. The Virtual Investor segment is accessible for viewing, providing more detailed insights into Xenetic's promising research advancements.